Stockreport

Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference [Yahoo! Finance]

Cabaletta Bio, Inc.  (CABA) 
PDF I/II datasets across systemic sclerosis, lupus nephritis and myasthenia gravis in H1, with potential FDA alignment to start a scleroderma pivotal study later this year. [Read more]